Vaxart Inc. [NASDAQ: VXRT] traded at a high on 05/07/21, posting a 3.90 gain after which it closed the day’ session at $7.20. The company report on May 7, 2021 that Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults.
Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population.
Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine.
The results of the trading session contributed to over 11695956 shares changing hands. Over the past one week, the price volatility of Vaxart Inc. stands at 18.20% while the volatility over the past one month is 14.15%.
The market cap for VXRT stock reached $724.39 million, with 109.82 million shares outstanding and 108.76 million shares in the current float. Compared to the average trading volume of 17.87M shares, VXRT reached a trading volume of 11695956 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vaxart Inc. [VXRT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VXRT shares is $13.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VXRT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Vaxart Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 12, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on July 13, 2020, representing the official price target for Vaxart Inc. stock.
The Average True Range (ATR) for Vaxart Inc. is set at 1.04, with the Price to Sales ratio for VXRT stock in the period of the last 12 months amounting to 181.10. The Price to Book ratio for the last quarter was 6.43, with the Price to Cash per share for the same quarter was set at 1.26.
How has VXRT stock performed recently?
Vaxart Inc. [VXRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -33.21. With this latest performance, VXRT shares gained by 26.98% in over the last four-week period, additionally plugging by 40.62% over the last 6 months – not to mention a rise of 183.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VXRT stock in for the last two-week period is set at 51.06, with the RSI for the last a single of trading hit 49.35, and the three-weeks RSI is set at 51.19 for Vaxart Inc. [VXRT]. The present Moving Average for the last 50 days of trading for this stock 6.52, while it was recorded at 7.66 for the last single week of trading, and 7.21 for the last 200 days.
Vaxart Inc. [VXRT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vaxart Inc. [VXRT] shares currently have an operating margin of -766.66. Vaxart Inc.’s Net Margin is presently recorded at -796.34.
Return on Total Capital for VXRT is now -35.02, given the latest momentum, and Return on Invested Capital for the company is -38.23. Return on Equity for this stock declined to -47.26, with Return on Assets sitting at -33.98. When it comes to the capital structure of this company, Vaxart Inc. [VXRT] has a Total Debt to Total Equity ratio set at 17.94. Additionally, VXRT Total Debt to Total Capital is recorded at 15.21, with Total Debt to Total Assets ending up at 14.51. Long-Term Debt to Equity for the company is recorded at 14.02, with the Long-Term Debt to Total Capital now at 11.89.
Reflecting on the efficiency of the workforce at the company, Vaxart Inc. [VXRT] managed to generate an average of -$1,150,714 per employee. Receivables Turnover for the company is 2.05 with a Total Asset Turnover recorded at a value of 0.04.Vaxart Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.90 and a Current Ratio set at 10.90.
Earnings analysis for Vaxart Inc. [VXRT]
With the latest financial reports released by the company, Vaxart Inc. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -100.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VXRT.
Insider trade positions for Vaxart Inc. [VXRT]
There are presently around $249 million, or 34.50% of VXRT stock, in the hands of institutional investors. The top three institutional holders of VXRT stocks are: STATE STREET CORP with ownership of 9,444,967, which is approximately 936.18% of the company’s market cap and around 0.60% of the total institutional ownership; BLACKROCK INC., holding 5,417,916 shares of the stock with an approximate value of $37.55 million in VXRT stocks shares; and VANGUARD GROUP INC, currently with $35.78 million in VXRT stock with ownership of nearly 3.363% of the company’s market capitalization.
Positions in Vaxart Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 92 institutional holders increased their position in Vaxart Inc. [NASDAQ:VXRT] by around 13,529,974 shares. Additionally, 52 investors decreased positions by around 15,716,238 shares, while 25 investors held positions by with 6,720,682 shares. The mentioned changes placed institutional holdings at 35,966,894 shares, according to the latest SEC report filing. VXRT stock had 42 new institutional investments in for a total of 1,861,801 shares, while 27 institutional investors sold positions of 6,740,284 shares during the same period.